MedTrace Logo

The Effect of Myo-inositol, Somatropin, and DHEA on Poor Ovarian Responders

NCT05900661 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2023-07-18

No results posted yet for this study

Summary

To evaulate the role of Myo-inositol, somatropin, DHEA on ICSI outcome in poor ovarian responder

Conditions

  • Poor Responders

Interventions

DRUG

myo-inositol

myo-inositol 600µgm + folic acid 0.2 mg) 2 capsules at the morning and 2 capsules at the evening on empty stomach for 12 weeks produced by a Lo.Li pharma international ,Rome.Italy .

DRUG

Somatropin

growth hormone 2:Somatropin (4 IU for 1month), SEDICO ,6th of october .Egypt. 1 s.c injection every 3 days for at least 1 month.

DRUG

Dehydroepiandrosterone

DHEA 50 mg twice per day for 12 weeks in the last group , NATROL UK.Ltd.

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Beni-Suef University · Faculty of Medicine Beni-Suef University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-30
Primary Completion
2023-09-30
Completion
2023-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05900661 on ClinicalTrials.gov